Outbreak of severe community-acquired bacterial infections from Streptococcus pyogenes, Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae among children in North Rhine-Westphalia (Germany), October to December 2022

Introduction

Since the outbreak of the COVID-19 pandemic in 2020, children’s and adolescents’ health has been challenged in numerous ways. Among others, a decline of bacterial infections and distorted periodicity of seasonal infection waves were observed across the world and affected all age groups.^1–5 An unforeseen result of reduced incidence of infections is the lack of natural immunity especially in the youngest.

Beginning in late fall 2022, rising numbers of severe bacterial infections caused by group A streptococci were reported from Spain, France, Great Britain, and other countries.^6–9 At the same time in Germany, a massive wave of acute viral and bacterial infections caused a near-collapse of the pediatric health care system including out- and inpatient sectors and - most dramatically - overwhelmed pediatric intensive care capacities.^10–12 Pediatric health care providers in Germany claimed that this was an unprecedented public health emergency.

This study was designed to assess the burden of hospitalizations due to community-acquired bacterial infections by Streptococcus pyogenes (S. pyogenes), Streptococcus pneumoniae (S. pneumoniae), Neisseria meningitidis (N. meningitidis), and Haemophilus influenzae (H. influenzae) in the last quarter of 2022 compared to seasonally expected infection waves since 2016; to identify driving pathogens, and describe disease severity and outcomes. Accordingly, we combined five data sources for comprehensive capture-recapture analyses: 1) A multicentre study (MC) conducted in 95 % of children’s hospitals in the most populated state of Germany (North Rhine-Westphalia [NRW]) in the last quarter of 2022; 2) long-term surveillance data from national reference laboratories for a) streptococci, b) N. meningitidis, and c) Haemophilus influenzae; as well as 3) publicly accessible population and death cause statistics provided by the German Federal Statistical Office (FSO, Statistisches Bundesamt, www.destatis.de).

Methods

Results

Fifty-nine of 62 (95 %) children’s hospitals in NRW participated in the MC study, comprising 4066 of 4323 (94 %) self-reported pediatric hospital beds during the study period. At the end of 2022, 22 % of Germany’s pediatric population lived in NRW. After subtracting the 6 % capacities from non-participating children’s hospitals, the participating centers supplied medical care for approximately 20.7 % of the German pediatric population.

A total of 153 cases were reported with a median patient age of 4 years (IQR 1 – 7) and 56 % (n = 86) males (Table 2). Fifty-eight (38 %) of the reported cases were associated with S. pyogenes, 62 (41 %) with S. pneumoniae, 2 (1 %) with N. meningitidis, 19 (12 %) with H. influenzae, and 12 (8 %) with other streptococcal species. The most frequent presentation was pneumonia (n = 91, 59 %), followed by sepsis/systemic inflammatory response syndrome/toxic shock syndrome (n = 28, 18 %), skin or soft tissue infections (n = 22, 14 %), and ear-nose-throat infections without cerebral invasion (n = 22, 14 %) (Table 2). Viral co-infections were observed in 71 (46%) cases, with variations depending on the bacterial pathogen (Table 2). Intensive care unit admissions were frequent (n = 90, 59%), as was mechanical ventilation (n = 67, 44 %), surgical source control (n = 41, 27 %), and use of vasopressors or inotropes (n = 26, 17 %) (Table 2). Substantial variation between pathogens was observed regarding clinical presentation and performed supportive therapies (Figure 1). Eight children died (5 %), and five patients (3 %) were discharged to a rehabilitation or care facility. Nonetheless, overall functional neurological outcome at hospital discharge in survivors was good (median pediatric cerebral performance category (PCPC) = 1, IQR 1 – 2).

• Download figure
• Open in new tab

Figure 1. Hospital-treated community-acquired bacterial infections in children in North Rhine-Westphalia in the last quarter of 2022

a) Clinical presentation

b) Treatment and outcomes

SIRS = systemic inflammatory response syndrome; TSS = toxic shock syndrome, ENT = ear-nose-throat; CNS = central nervous system; ICU = intensive care unit; CPR = cardiopulmonary resuscitation

Capture-recapture analyses showed different degrees of overlap between the conducted MC study and the NRL surveillance data. For N. meningitidis, complete capture by the NRL was achieved, but the total case number (n = 6) was comparatively low, especially when compared to case estimates of S. pneumoniae (n_estimated = 232), S. pyogenes (n_estimated = 214), and H. influenzae (n_estimated = 95) (Table 3).

With onset of the COVID-19 pandemic, monthly S. pyogenes case numbers reported to the NRLS, monthly incidence rates and IRRs dropped, remained low until September 2022 and peaked in December 2022 (IRR 18.3 (95 % CI 6.3 – 88.8)) as well as March 2023 (IRR 14.7 (5.7 – 54.0)) (Figure 2a and S1a). S. pneumoniae also showed a decline during pandemic years but seasonal variations remained present throughout the three-year period, with a remarkable peak in December 2022 (IRR 2.7 (1.7 – 4.7)) and February 2023 (IRR 3.2 (2.0 – 5.5)) (Figure 2b and S1b). For N. meningitidis, overall case numbers were fairly low and no clear trend was observed throughout the observation period except for an increase in March 2023 (IRR 1.7 (1.0 – 3.1)) (Figure 2c and S1c). H. influenzae, on the other hand, remained mainly within the seasonally expected ranges except for November 2022 (IRR 7.8 (2.2 – 64.8)) and February 2023 (IRR 2.9 (1.1 – 10.8)) (Figure 2d and S1c). Overall, incidence rates and IRRs exhibited a decline at the onset of the pandemic, followed by a pathogen-specific degree of recovery, reaching or surpassing pre-pandemic levels (Figure S1 and supplementary table). Cumulative monthly incidence rates and IRRs declined at the beginning of the pandemic, showed small peaks during the course of the pandemic, and peaked in December 2022 and February 2023 (Figure 3 and supplementary table).

• Download figure
• Open in new tab

Figure S1. Monthly incidence rate ratios of invasive bacterial infections in children in North Rhine-Westphalia January 2020 -March 2023 (reference period 2016 – 2019)

a) S. pyogenes

b) S. pneumoniae

c) N. meningitidis

d) H. influenzae

• Download figure
• Open in new tab

Figure 2. Hospitalizations for community-acquired bacterial infections

a) S. pyogenes

b) S. pneumoniae

c) N. meningitidis

d) H. influenzae

Red solid line: incidence rates January 2020 - March 2023; black dashed line and grey band: average monthly incidence rates 2016 - 2019 with 95 % CI; green band: period of MC study

• Download figure
• Open in new tab

Figure 3. Hospitalizations due to acquired-bacterial infections from S. pyogenes, S. pneumoniae, N. meningitidis, and H. influenzae, January 2020 - March 2023

a) Cumulative hospitalization rates of S. pneumoniae (dark grey), S. pyogenes (medium grey), and N. meningitidis + H. influenzae (light grey)

b) IRRs of infections, reference period 2016 – 2019 Green band: period of MC study

During the three-month MC study, the reported number of deaths in children < 15 years of age exceeded the expected number of deaths from bacterial infections for the entire year in NRW (7 observed; 1 expected). The causative pathogens were identified as S. pyogenes and S. pneumoniae, while no deaths were caused by N. meningitidis (2 expected) (Table 4).

Discussion

This multi-source study in Germany’s most populous federal state detected a high burden of pediatric general ward and pediatric intensive care unit admissions for bacterial infections associated with S. pyogenes, S. pneumoniae, N. meningitidis, and H. influenzae in the last quarter of 2022. Disease severity was high with more than half of the cases admitted to an intensive care unit and frequent requirement of invasive mechanical ventilation and vasoactive agents. Longitudinal assessment since 2016 revealed an unprecedented peak of bacterial infection-related hospitalizations in late 2022 and early 2023, primarily driven by S. pyogenes and S. pneumoniae. Deaths during the three-month period of the MC study were seven times higher than expected for the entire year according to pre-pandemic death cause statistics.

A major finding that has already been reported in adults and children^{13, 14} was the marked overall decline of severe and invasive bacterial infections at the beginning of the COVID-19 pandemic. According to our study, this overall decline was shortly interrupted in fall 2021 but otherwise lasted until early summer 2022 when compulsory wearing of protective face masks was abrogated. However, decline patterns differed between the four bacterial pathogens examined in this study and were likely influenced by other factors than protective face masks.^{13, 15–20}

The decline of S. pyogenes infections from the onset of the pandemic until spring 2022 was also reported in France, followed by a sudden increase of non-invasive S. pyogenes infections.²¹ Similar to Germany, France and England also witnessed strong increases of severe and invasive S. pyogenes infections during fall and winter of 2022.^{7, 22} These surges were most likely induced by an overall rise in infection numbers with the proportion of severe cases remaining constant, rather than changes in types, virulence or toxicity.^{7, 23–25} A possible explanation is the discontinuation of face mask wearing among children, which re-enabled droplet transmission of S. pyogenes, an essential mechanism of infection.²⁶ Acute viral infections paving the way for bacterial superinfections are an additional factor potentially contributing to the severity of the S. pyogenes infection wave. This constellation is described for influenza virus in combination with S. pyogenes and S. pneumoniae ²⁷ and was also observed in our study. The theory of superinfections as partial drivers of the surge is supported by the rise in consultations and hospitalizations for severe acute respiratory disease in children and adolescents during the peak of S. pyogenes infections in Germany in late 2022 reported by the Robert Koch-Institute.²⁸

Viral infections likely also promoted the increase of S. pneumoniae infections. Asymptomatic S. pneumoniae carriage and respiratory virus infection as starting point for invasive pneumococcal disease is well-described.²⁹ Our study found viral co-infections in 60 % of the S. pneumoniae cases, with influenza and respiratory syncytial virus as the most common. During the pandemic years, the decline in pneumococcal infections in Germany was less consistent compared to the drop in S. pyogenes infections, possibly explained by viral infection waves among children in spite of the pandemic measures.²⁸ In contrast to S. pyogenes infections, invasive pneumococcal disease can be effectively prevented by vaccination.³⁰ Consequently, it is crucial to establish and maintain high levels of vaccination rates to attenuate future outbreaks triggered by viral waves. In Germany, pneumococcal vaccination coverage for children entering primary school increased from 15 % in 2010 to 83 % in 2017-2019 but is as low as 2 % in the age group from 16 to 59 years, even in patients who suffer from high-risk clinical conditions.^{31, 32} Of infants born in 2016, only 73 % received a full series of the recommended pneumococcal vaccination scheme, vaccinations were frequently delayed, and nearly a quarter of infants did not receive a booster dose.³³ This low vaccination coverage calls for urgent improvement to enhance protection against opportunistic pneumococcal infections during large-scale viral waves that are expected to persist in the post-SARS-CoV-2 era.

Vaccines are also responsible for decreasing incidence rates of meningococcal infections with marked replacement by non-vaccinated serogroups W and Y in several countries.³⁴ In Germany, vaccination is recommended for serogroup C with an according decline of serogroup C infections since its introduction.³⁵ The trend of overall decreasing meningococcal disease was further enhanced during the COVID-19 pandemic ¹³ and also noticeable in our study with incidence rates below pre-pandemic average. Yet, in March 2023, an increase in meningococcal infection incidence above average was observed but characterized by very low absolute numbers. In contrast to S. pneumoniae, vaccine coverage against meningococcal serogroup C in school starters in Germany is above 90 %.³² Unfortunately, no data are available on N. meningitidis serogroup B, but vaccine coverage is likely to be very low because vaccination is not officially recommended and thus not routinely covered by health insurances.

In the Netherlands, a decline of invasive infections during the COVID-19 pandemic was observed for H. influenzae, unfortunately associated with an increase of vaccine-preventable serotype b.³⁶ In our study, H. influenzae hospitalizations during the pandemic remained within seasonally expected ranges, showing only two peaks in December of 2021 and 2022, respectively. However, despite vaccine coverage of 90 % in German children against H. influenzae b ³², IRRs have remained almost constantly above one since June 2021, indicating a slight increase of non-vaccinated H. influenzae infections that contribute to the overall burden of pediatric hospitalizations, especially during seasonal waves of acute respiratory diseases.

Limitations of the study mainly derive from missing cases: Due to the incomplete coverage of children’s hospitals in NRW, the MC study missed 6 % of pediatric hospital capacities. Cases treated outside of pediatric units, such as otorhinolaryngology or adult units, and pre-hospital deaths could not be captured, potentially leading to underestimation of incidences and disease severity. Variable pathogen-specific underreporting to the NRLs was also observed, which is acknowledged for infectious disease surveillance.^37–39

In summary, the acute overload of the German pediatric health care system was caused by a post-pandemic rebound of acute viral and bacterial respiratory and invasive diseases that peaked at the same time, creating a fatal combination that caused an unprecedented incidence of hospitalizations in children. Shortages of essential drugs in the outpatient sector ^{40, 41} and a decrease in numbers of operable beds in children’s hospitals due to long-anticipated personnel shortages ^{42, 43} aggravated this pediatric health care crisis.

The results of this study present another piece of evidence that the side effects from preventive measures against the COVID-19 pandemic are at least on par with the harm children experienced from the novel coronavirus itself. While this is already well-acknowledged for mental health and obesity, which directly increase morbidity but not mortality ^44–47, the wide-spread and drastic increase of severe and fatal bacterial infections in developed countries is new. Worldwide shortages of antibiotics for children ^{40, 41} complicated early treatment in the outpatient setting, which may have caused exacerbation of some cases. Despite good overall functional neurological outcomes observed in this study, non-neurological long-term sequelae, especially poststreptococcal autoimmune disorders, may continue to burden the health care system for years.

Further research should untangle this amalgam to quantify excess morbidity and mortality that result from acute bacterial infections themselves and from the failure to provide adequate pediatric care capacities in Germany. However, even more urgent than scientific workup, is the introduction of effective measures against future outbreaks among children to prevent morbidity and deaths. These include high vaccination coverage, opportunity to acquire natural immunity against viral and bacterial disease, sufficient pediatric drug supply, and pediatric health care capacities adapted to seasonal demands.

Article Summary

In late 2022 and early 2023, hospitalizations for bacterial infections dramatically increased, causing deaths and contributing to a near-collapse of the pediatric health care system.

What’s Known on This Subject

During the COVID-19 pandemic, incidences of bacterial infections strongly declined. In late 2022, several European countries observed strongly rebounding incidences of invasive infections from group A streptococci.

What This Study Adds

This study found up to 18-fold incidence rates of S. pyogenes in late 2022 and early 2023, accompanied by surges of S. pneumoniae and partially H. influenzae. Deaths were seven times higher than expected.

Contributors Statement Page

Drs. Sarah C. Goretzki and Nora Bruns conceptualized and designed the study, carried out analyses, drafted the initial manuscript, and critically reviewed and revised the manuscript.

Drs Tom Hühne, Roland O. Adelmann, Firas Ala Eldin, Mohamed Albarouni, Jan-Claudius Becker, Michael A. Berghäuser, Thomas Boesing, Michael Boeswald, Milian Brasche, Francisco Brevis, Rokya Camara, Clara Deibert, Frank Dohle, Jörg Dolgner, Jan Dziobaka, Frank Eifinger, Natalie Elting, Matthias Endmann, Holger Frenzke, Monika Gappa, Bahman Gharavi, Christine Goletz, Eva Hahn, Yvonne Heidenreich, Konrad Heimann, Hans-Georg Hoffmann, Marc Hoppenz, Gerd Horneff, Helene Klassen, Cordula Körner-Rettberg, Pascal Lenz, Klaus Lohmeier, Andreas Müller, Frank Niemann, Michael Paulussen, Falk Pentek, Ruy Perez, Markus Pingel, Philip Repges, Tobias Rothoeft, Jochen Rübo, Herbert Schade, Robert Schmitz, Peter Schonhoff, Jan N. Schwade, Tobias Schwarz, Peter Seiffert, Georg Selzer, Uwe Spille, Carsten Thiel, Ansgar Thimm, Bartholomäus Urgatz, Alijda van den Heuvel, Tan van Hop, Verena Giesen, Stefan Wirth, Thomas Wollbrink, Daniel Wüller and Profs. Guido Engelmann, Kai O. Hensel, Alfred Längler, collected data and critically reviewed and revised the manuscript.

Drs. Mark van der Linden, Andreas Itzek, Heike Claus and Thiên-Trí Lâm collected data, carried analyses, and critically reviewed and revised the manuscript.

Profs. Ursula Felderhoff-Müser and Christian Dohna-Schwake conceptualized and designed the study, coordinated and supervised data collection, and critically reviewed and revised the manuscript for important intellectual content.

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.